PMID- 30160189
OWN - NLM
STAT- MEDLINE
DCOM- 20200129
LR  - 20200129
IS  - 2295-3337 (Electronic)
IS  - 1784-3286 (Linking)
VI  - 74
IP  - 5
DP  - 2019 Oct
TI  - Improvements in productivity and increased participation in daily activities over 
      52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a 
      Belgian observational study.
PG  - 342-350
LID - 10.1080/17843286.2018.1509923 [doi]
AB  - Objectives: To report changes in productivity and social participation - 
      alongside clinical and patient-reported outcomes (PROs) - in patients with 
      rheumatoid arthritis (RA) receiving certolizumab pegol (CZP) during routine 
      clinical practice in Belgium. Methods: This was a prospective, non-interventional 
      study, in which patients were prescribed CZP at their physicians' discretion and 
      followed during routine clinical visits. The primary outcomes were household 
      productivity and social participation at the last visit (~52 weeks), measured 
      through responses to the Work Productivity Survey. Secondary outcomes included 
      workplace productivity and achievement of DAS28(ESR) clinical response, low 
      disease activity and remission at the last visit. Baseline demographics and 
      adverse events (AEs) were recorded for all patients who received >/=1 dose CZP. 
      Results: A total of 141 patients were enrolled in the study, of whom 119 (84.4%) 
      formed the full analysis set (received >/=1 dose CZP and had >/=1 post-baseline 
      measurement for >/=1 primary outcome). At Visit 1 (baseline), patients reported an 
      average of 11.0 paid work days, 16.8 household work days and 5.5 days of social 
      participation affected by their disease over the previous month. Rapid 
      improvements in household productivity and social participation were evident from 
      Visit 2 (2-8 weeks). By the final visit, mean improvements were observed for all 
      aspects of productivity, participation and clinical/PROs. A total of 24 AEs were 
      reported. Conclusion: CZP has a positive impact on productivity and social 
      participation in patients with RA in the Belgian daily practice setting, with 
      safety and efficacy profiles that mirror those observed in the trial setting.
FAU - Westhovens, Rene
AU  - Westhovens R
AD  - Department of Development and Regeneration, Skeletal Biology and Engineering 
      Research Center, KU Leuven , Leuven , Belgium.
AD  - Rheumatology, University Hospitals Leuven , Leuven , Belgium.
FAU - Ravelingien, Isabelle
AU  - Ravelingien I
AD  - Department of Rheumatology, Onze-Lieve-Vrouw Ziekenhuis Aalst , Asse, Aalst , 
      Belgium.
FAU - Vandevyvere, Klaas
AU  - Vandevyvere K
AD  - Reumakliniek MedSeen , Houthulst , Belgium.
FAU - Pansar, Ingrid
AU  - Pansar I
AD  - UCB Pharma , Brussels , Belgium.
FAU - Purcaru, Oana
AU  - Purcaru O
AD  - UCB Pharma , Brussels , Belgium.
FAU - Kumke, Thomas
AU  - Kumke T
AD  - UCB Pharma , Monheim am Rhein , Germany.
FAU - Gyselbrecht, Lieve
AU  - Gyselbrecht L
AD  - Algemeen Stedelijk Ziekenhuis , Aalst , Belgium.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20180830
PL  - England
TA  - Acta Clin Belg
JT  - Acta clinica Belgica
JID - 0370306
RN  - 0 (Antirheumatic Agents)
RN  - UMD07X179E (Certolizumab Pegol)
SB  - IM
MH  - Activities of Daily Living
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Belgium
MH  - Certolizumab Pegol/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Efficiency
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Reported Outcome Measures
MH  - Prospective Studies
MH  - Social Participation
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Rheumatoid arthritis
OT  - certolizumab pegol
OT  - non-interventional
OT  - productivity
OT  - social participation
EDAT- 2018/08/31 06:00
MHDA- 2020/01/30 06:00
CRDT- 2018/08/31 06:00
PHST- 2018/08/31 06:00 [pubmed]
PHST- 2020/01/30 06:00 [medline]
PHST- 2018/08/31 06:00 [entrez]
AID - 10.1080/17843286.2018.1509923 [doi]
PST - ppublish
SO  - Acta Clin Belg. 2019 Oct;74(5):342-350. doi: 10.1080/17843286.2018.1509923. Epub 
      2018 Aug 30.